50 results about "Eosinophilic esophagitis" patented technology

Described herein are methods of managing eosinophilic esophagitis (EoE) in a patient, wherein the patient records the number of episodes of dysphagia on a patient report outcome (PRO) questionnaire prior to and during the course of treatment. While on treatment, the number of episodes of dysphagia are reduced, as reported on the PRO questionnaire. In some embodiments, the esophageal eosinophils are counted before or after treatment, or both. In some embodiments, esophageal eosinophils counts are not correlated with a reduction in the episodes of dysphagia.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The present invention provides Irsogladine or a pharmaceutically acceptable salt thereof for use in the treatment and / or prevention of eosinophilic gastrointestinal diseases in mammals. The invention is useful in the treatment of eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic duodenitis, eosinophilic enteritis, eosinophilic colitis, and in particular, eosinophilic esophagitis. The invention is particularly useful for inducing disease remission in acute inflammatory activity and long-term maintenance of remission as well. The Irsogladine of the invention can be administered in the form of a pharmaceutical composition, or more specifically, in the form of an oral and rectal pharmaceutical composition.

The invention relates to the technical field of compositions, and particularly discloses a composition for assisting in improving eosinophilic esophagitis and application of the composition. The composition for assisting in improving eosinophilic esophagitis provided by the invention comprises an iron source, a zinc source and L-carnitine. By optimizing the components of the composition and specifically limiting the proportion of the iron source, the zinc source and the L-carnitine in the composition, esophageal epithelial hyperplasia can be effectively reversed, the number of bifidobacteria is increased, the number of enterobacter and esophageal tissue eosinophilic granulocytes is reduced, the level of IL-13 cell factors is reduced, and the curative effect is improved. Further, the effect of remarkably assisting in improving eosinophilic granulocytic esophagitis is achieved.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

The invention provides methods for diagnosing eosinophilic esophagitis (EoE) in a subject and methods for determining an EoE state (active or remission) in a subject. The methods include detecting elevated expression levels of GPR15 protein or a fragment thereof and / or CD38 protein or a fragment thereof in a biological sample from the subject. Panels, compositions, and kits are also provided.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen- specific binding site that specifically binds KLK5 and KLK7 and at least one antigen- specific binding site that specifically binds to OX40L or receptor thereof.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Aspects of this application provide bispecific antibodies and methods of using them for treating conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis, by promoting barrier function and reducing inflammation. In some embodiments, the bispecific antibody includes at least one antigen-specific binding site that specifically binds to KLK5 and KLK7, and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or its receptor.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

Aspects of this application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies), as well as methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.

Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present invention relates to a water-soluble film containing mometasone furoate, adjusted to a pH in the range of 3.5 to 5.0. Adjusting the pH improves the stability of the active ingredient without significantly affecting the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing such films in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can be used, in particular, for the treatment of eosinophilic esophagitis.

Aspects of the application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5xKLK7 antibodies (e.g., bispecific antibodies) and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

The invention provides application of quercetin in preparation of a medicine for treating eosinophilic oesophagitis, and belongs to the technical field of biological medicine. The invention provides application of quercetin in preparation of a medicine for treating eosinophilic esophagitis, and intervention on the EoE pathological process is realized by systematically relieving clinical symptoms of diseases, inhibiting esophageal tissue pathological injury, blocking the fibrosis process, regulating local inflammation and immune balance and down-regulating biomarker expression. The application has the core value that quercetin is applied to EoE treatment for the first time, the treatment effect of quercetin is defined, a brand new choice is provided for an existing acidophilic cell esophagitis treatment method, and meanwhile treatment indications of quercetin are perfected.

The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and / or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and / or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

Provided are combination dosing regimens comprising administering a monoclonal antibody, such as dupilumab, and hyaluronidase. Combinations and compositions containing the monoclonal antibody and hyaluronidase are provided. The dosing regimens and combinations with dupilumab are for treating or preventing allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis, eosinophilic esophagitis, and prurigo nodularis.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

To provide a suitable means for delivering a therapeutic biomolecule to a patient, wherein a stable and therapeutically effective blood level of the biomolecule occurs in a stable and convenient form over an extended period of time.SOLUTION: Provided is a device for treating a disease in a subject, wherein the subject may have Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, eosinophilic esophagitis, autoimmune hepatitis, the device comprising a cell chamber comprising a population of cells that secrete a biomolecule for delivery to the subject.SELECTED DRAWING: None

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

Aspects of the present application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies) and methods of using them to promote barrier function and reduce inflammation and to treat conditions such as Neethton Syndrome, eosinophilic esophagitis, and atopic dermatitis.

Provided herein are compositions and methods for the individualized identification of triggers allergies (e.g., non-IgE mediated allergies) in an individual. In particular, biomarkers and assays are provided and used to characterize food allergies and related conditions (e.g., food protein-induced enterocolitis syndrome (FPIES), eosinophilic esophagitis (EoE), etc.) in an individual, by identifying safe and trigger foods without the need for oral challenge.

The present invention relates to a water-soluble film having a mometasone furoate content adjusted to a pH in the range of 3.5 to 5.0. The correspondingly adjusted pH increases the stability of the active ingredient without substantially impairing the mechanical properties of the film. The present invention further relates to methods for producing such films, pharmaceutical dosage forms containing films of the above type in a capsule, and methods for producing such pharmaceutical dosage forms. The pharmaceutical dosage form can especially be used for treating eosinophilic esophagitis.

The present invention relates to an anti-human interleukin-4 receptor A antibody, a pharmaceutical composition thereof or a kit, and an application thereof in the treatment of eosinophilic esophagitis.